PULMATRIX, INC. Net Income (Loss) Available to Common Stockholders, Basic
PULMATRIX, INC. (PULM) reported Net Income (Loss) Available to Common Stockholders, Basic of -$1.05 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-09-17
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$1.05M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$1.55M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$9.83M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$3.16M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$18.84M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$23.37M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$19.31M.
- PULMATRIX, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$27.84M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.05M S-4/A · filed 2026-09-17 | -$2.22M S-4/A · filed 2026-09-17 | ||
| 2025-06-30 | -$1.55M S-4/A · filed 2026-09-17 | -$3.36M S-4/A · filed 2026-09-17 | ||
| 2022-12-31 | -$18.84M 10-K · filed 2023-03-30 | |||
| 2021-12-31 | -$23.37M 10-K · filed 2023-03-30 | |||
| 2020-12-31 | -$19.31M 10-K · filed 2022-03-29 | |||
| 2016-12-31 | -$9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$12.99M derived: sum of 2 quarters · filed 2017-03-10 | -$22.17M derived: sum of 3 quarters · filed 2017-03-10 | -$27.84M 10-K · filed 2017-03-10 |
| 2016-09-30 | -$3.16M 10-Q · filed 2016-11-04 | -$12.34M derived: sum of 2 quarters · filed 2016-11-04 | -$18.01M 10-Q · filed 2016-11-04 | -$22.55M derived: sum of 4 quarters · filed 2017-03-10 |
| 2016-06-30 | -$9.19M 10-Q · filed 2016-08-04 | -$14.86M 10-Q · filed 2016-08-04 | -$19.39M derived: sum of 3 quarters · filed 2017-03-10 | -$24.32M derived: sum of 4 quarters · filed 2017-03-10 |
| 2016-03-31 | -$5.67M 10-Q · filed 2016-05-05 | -$10.21M derived: sum of 2 quarters · filed 2017-03-10 | -$15.14M derived: sum of 3 quarters · filed 2017-03-10 | -$30.03M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-12-31 | -$4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$9.47M derived: sum of 2 quarters · filed 2017-03-10 | -$24.36M derived: sum of 3 quarters · filed 2017-03-10 | -$26.17M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$4.93M 10-Q · filed 2016-11-04 | -$19.83M derived: sum of 2 quarters · filed 2016-11-04 | -$21.63M 10-Q · filed 2016-11-04 | -$6.46M derived: sum of 4 quarters · filed 2016-11-04 |
| 2015-06-30 | -$14.90M 10-Q · filed 2016-08-04 | -$16.70M 10-Q · filed 2016-08-04 | -$1.53M derived: sum of 3 quarters · filed 2016-08-04 | -$12.67M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | -$1.80M 10-Q · filed 2016-05-05 | $13.37M derived: sum of 2 quarters · filed 2016-05-05 | $2.22M derived: sum of 3 quarters · filed 2016-05-05 | -$4.73M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | $15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $4.03M derived: sum of 2 quarters · filed 2016-03-10 | -$2.93M derived: sum of 3 quarters · filed 2016-03-10 | -$6.45M 10-K · filed 2016-03-10 |
| 2014-09-30 | -$11.15M 10-Q · filed 2015-11-12 | -$18.10M derived: sum of 2 quarters · filed 2015-11-12 | -$21.63M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$6.95M 10-Q · filed 2015-08-14 | -$10.48M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |